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Summary
Objective: The transglutaminase (TG) isoenzyme TG2, which catalyzes protein cross-linking via transamidation, inﬂuences healing phenotype
in multiple forms of tissue injury. Moreover, TG2 knockout suppresses cartilage destruction but promotes osteophyte formation in instability-
induced mouse knee osteoarthritis (OA). TG2 is marker of growth plate chondrocyte hypertrophy. Moreover, TG2 secreted by chondrocytes
acts in part by promoting chondrocyte maturation to hypertrophy, a differentiation state linked with MMP-13 expression and disease progres-
sion in OA. Moreover, glucosamine, which is currently under investigation as an OA therapy, binds and inhibits TG2. Here, we examined TG2
as a potential marker of cartilage hypertrophy in the spontaneous guinea pig model of OA.
Methods: Synovial ﬂuid ELISA and cartilage Immunohistochemistry and quantitative Reverse transcription-polymerase chain reaction (RT-
PCR), were used to examine TG2 expression and TG transamidation-catalyzed isopeptide bonds.
Results: TG isopeptide bonds and TG2 were most abundant in articular cartilage in early knee OA. TG2 expression was robust at sites of early
but not established osteophytes. Synovial ﬂuid TG2 correlated with knee OA total histological score (r¼ 0.47, P¼ 0.01), as did medial tibial
plateau cartilage TG2 mRNA (r¼ 1.0, P¼ 0.003). At 12 months of age, medial tibial plateau cartilage TG2 mRNA expression rose markedly in
association with elevated type X collagen, as well as ADAMTS-5, and MMP-13 expression, changes not shared in age-matched Strain 13
guinea pigs that are less susceptible to knee OA.
Conclusion: Hartley guinea pig knee TG2 expression associates with enhanced articular chondrocyte hypertrophy and is a biomarker of OA
severity.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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Alterations in extracellular matrix and matrix-cell communi-
cation, and in mediators of inﬂammation, regulate the differ-
entiation, viability, and tissue remodeling functions of
articular cartilage chondrocytes, thereby modulating OA
clinical phenotype and outcome1e8.
Transglutaminase 2 (TG2)9e13 belongs to a family of en-
zymes that catalyze calcium-dependent transamidation,
generating covalent cross-links of available substrate gluta-
mine residues with primary amino groups (EC 2.3.2.13)14.
Transamidation modiﬁes proteins including ﬁbronectin and
collagens that have available substrate amino acids, and
TGs thereby alter proteineprotein interactions14. TGs are
classic wound repair enzymes implicated as essential for
tissue remodeling reactions to injury such as pulmonary
and dermal ﬁbrosis, cardiac hypertrophy, and reshaping of
injured arteries14. Aging alone, IL-1b, TNFa, as well as nitric
oxide, peroxynitrite donors, and certain chemokines induce
TG activity in chondrocytes9,11e13. Articular chondrocytesaThese authors contributed equally to the work.
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1056express not only TG2, but also the more tissue-restricted
TG isoenzyme, FXIIIA9e13.
Increased FXIIIA and TG2 expression and release are
associated with physiologic maturation to hypertrophy of
growth plate chondrocytes15,16. The growth plate chondro-
cyte hypertrophy functional program remodels the extracel-
lular matrix, partly through a shift in cartilage-speciﬁc
collagens from type II to type X collagen as well as by en-
hanced MMP-13 and ADAMTS-5 and diminished aggrecan
expression15,16. Articular cartilage chondrocytes are physio-
logically in a maturationally arrested state, but hypertrophic
differentiation develops within the population of human OA
chondrocytes in situ17. Chondrocyte hypertrophy also de-
velops within the ﬁrst few weeks in experimental joint insta-
bility-induced mouse knee OA and promotes disease
progression, as demonstrated in studies of runx2-deﬁcient
mice18.
TG2 and FXIIIA expression, as well as total TG catalytic
activity and TG-catalyzed isopeptide bond formation, are
substantially increased in human knee OA cartilage chon-
drocytes9,10,19. TG2 is essential to accelerate cultured
chondrocyte maturation to hypertrophy in response to sig-
nals provided by retinoic acid, CXCL1, the calgranulin
S100A11, and FXIIIA12,20e22. Externalization of TG2 is es-
sential to this activity13. Moreover, exogenous nanomolar
TG2 is sufﬁcient to directly induce hypertrophic differentia-
tion in chondrocytes in articular cartilage organ culture13.
1057Osteoarthritis and Cartilage Vol. 17, No. 8Yet, it is not known how TG2 is secreted, since it lacks a sig-
nal peptide14.
Secreted biomarkers detectable in the joint ﬂuid, serum,
or urine, that reﬂect initial, pre-radiographic stages of OA
have the potential to help stratify risk of progression, moni-
tor disease course, and improve efﬁcacy of OA therapeu-
tics23e26. TG2 release is critical for determining the repair
phenotype of multiple forms of tissue injury14,27,28. Further-
more, TG2 knockout was recently observed to suppress
cartilage destruction but to promote osteophyte formation
in a model of surgical instability-induced severe mouse
knee OA29. In addition, glucosamine, currently being inves-
tigated as an OA therapeutic30, binds TG2 and (at low mil-
limolar concentrations) inhibits TG2, acting more effectively
on cell-associated rather than free TG2, and modulating
TG2 conﬁrmation more than amine transfer31. Therefore,
this study tested the hypothesis that TG2 is a biomarker
of cartilage hypertrophy and OA severity. We employed
the well-characterized Hartley guinea pig model of sponta-
neously occurring OA, which has several similarities to
the development of OA in humans32e39. We observe TG2
to be a biomarker of OA severity in Hartley guinea pig
knees.Materials and methodsSAMPLE COLLECTIONAll aspects of this study were humane and approved at the Institutional
Animal Care and Use Committee level. Male Hartley guinea pigs were ob-
tained from Charles River Laboratories at 2 months age and sacriﬁced at
2, 4, 7, 10, 12 (n¼ 6 each) and 18 months (n¼ 10). Animals were housed
in solid bottom cages and fed water ad libitum and standard guinea pig
chow (Purina Lab Diet 5025) containing Vitamin C (1 mg/g) and Vitamin
D3 (3.4 IU/g)
36. All animals were acclimated to housing conditions for at least
1 week prior to sample collection. Synovial ﬂuid was collected from both
knees, pooled and stored at 80 C until analyzed as described35.
One knee joint was prepared for histological grading and cartilage was
harvested separately from the medial and lateral compartments of the other
knee joint, pooling cartilage from each time point to provide a quantity of tis-
sue sufﬁcient for RNA isolation and subsequent production of cDNA.HISTOLOGICAL ANALYSESKnee joints were prepared for histological analyses as described36. Par-
afﬁnized coronal sections (5 microns) of the central region of the joint were
stained with toluidine blue and grading of sections of each knee was per-
formed independently by two blinded observers (JLH, VBK) using a previ-
ously described, modiﬁed Mankin grading scheme35. Histological evidence
of chondropathy was assessed by grading of articular cartilage structure (ir-
regularities such as ﬁbrillation, the presence of clefts, and loss of cartilage
[0e8]), and proteoglycan loss (as determined by loss of toluidine blue stain-
ing [0e6]). The sum of articular cartilage structure and proteoglycan loss was
tabulated for the tibial and femoral condyles for the medial compartment, the
lateral compartment, and the whole joint (medial and lateral compartments).
The possible total score for each compartment ranged from 0 (normal) to 14
(severe structural damage and complete loss of toluidine blue staining),
hence possible whole joint scores ranged from 0 to 56.IMMUNOHISTOCHEMISTRYImmunohistochemical analyses utilized monoclonal antibodies (mAbs)
speciﬁc for guinea pig TG2 (#MS-224-P, Lab Vision, Fremont, CA), FXIIIA
(#MS 1237-P1. Lab Vision, Fremont, CA), N-epsilon gamma glutamyl lysine
(#ab424, Abcam Inc, Cambridge, MA), the isopeptide bond formed speciﬁ-
cally by TG activity, MMP-13 (mAb 3C5, kindly provided by Dr. Peter Mitch-
ell), and Type X collagen (#LSL-LB-0092, Cosmo-Bio, Tokyo). Sections were
deparafﬁnized and hydrated using xylene and a graded alcohol series fol-
lowed by incubation with 0.3% hydrogen peroxide to quench any endoge-
nous peroxidase activity. Sections used only for staining with TG2 mAb
required use of the citrate buffer epitope retrieval method to break the protein
cross-links formed by formalin ﬁxation of the tissue. Sections were covered
with 10 mM citrate buffer, pH 6.0, heated in a microwave for 5 s, and the
buffer was replaced and sections were heated for an additional 5 s, allowed
to cool, and then rinsed in Phosphate Buffered Saline (PBS).Immunohistochemical staining was done according to manufacturer instruc-
tions using the Vectastain ABC kit (#PK-4002, Vector Laboratories, Burlin-
game, CA). The sections were incubated with antibody to TG2 or FXIIIA
(2 mg/ml), the N-epsilon gamma glutamyl lysine mAb (20 mg/ml), MMP-13
mAb (diluted 1:50), Type X Collagen (diluted 1:100), or normal horse serum
as negative control.BIOMARKER ANALYSES BY ELISADirect ELISA, using biotin-labeled TG2-speciﬁc antibody CUB7402 or
FXIIIA speciﬁc antibody (Neomarkers, Freemont, CA)21, was used to quan-
tify synovial ﬂuid levels of TG2 and FXIIIA protein21 in studies of samples
previously analyzed for COMP by ELISA38. The ﬂuids were concentrated
with 100% Trichloroacetic acid (TCA), and the pellet was then washed, sol-
ubilized and dissolved in buffer, and the protein was bound to a Nunc ELISA
plate overnight at 4 C. Plates were then blocked with 3% Bovine Serum Al-
bamin (BSA) in 150 mM NaCl, 10 mM Tris, Ph 8.0, 0.05% Tween-20, fol-
lowed by incubation with biotin-labeled antibody. Strepavidinealkaline
phosphatase (AP) was added and the amount of TG2 or FXIIIA quantiﬁed
at OD 405 nm after addition of AP substrate.REAL-TIME QUANTITATIVE PCRCartilage was harvested separately from the medial and lateral compart-
ments of the knee joint, pooling cartilage from each time point to provide
a quantity of tissue sufﬁcient for RNA isolation and subsequent production
of cDNA utilized for the quantiﬁcation of gene expression by real-time
qPCR. Following ampliﬁcation, a monocolor relative quantiﬁcation of the tar-
get gene and reference (18S) analysis determined the normalized target
gene: 18S mRNA copy ratios by the manufacturer’s LightCycler Software
(Version 4.0). The primers employed were designed using LightCycler Probe
software, version 2.0 (Roche, Diagnostics, Indianapolis, IN).STATISTICAL ANALYSESData were examined for correlations with total joint histological score us-
ing GraphPad Prism 4.0. Pearson correlation was used to evaluate the rela-
tionship of synovial ﬂuid levels of TG2 and FXIIIA to total histological score
and the non-parametric Spearman correlation was used to calculate the cor-
relation of mRNA values to total histological score. Multiple regression mod-
eling was performed in JMP Statistical Software Package (JMP) (SAS,
Cary, NC) and used to evaluate the association of these biomarkers with his-
tological OA severity, controlling for age, weight, and serum COMP, with
P-value 0.05 considered signiﬁcant. Statistical analyses of quantitative
mRNA expression employed the Student’s t-test for paired samples
(Fig. 4) and log transformation of the data followed by a two-tailed unpaired
Student’s t-test comparing Strain 13 to Hartley guinea pigs (Fig. 5).ResultsLOCALIZATION OF TG2, FXIIIA, AND N-EPSILON GAMMA
GLUTAMYL LYSINE CROSS-LINKS IN HARTLEY GUINEA
PIG KNEE CARTILAGEThe development of spontaneous knee OA in the Hartley
guinea pig knee begins as early as 3 months of age, when
loss of proteoglycans typically becomes apparent39. We ob-
served the characteristic progression of OA histological
changes from 4 to 12 months of age in the Hartley guinea
pig medial tibial plateau articular cartilage ranging from
a score of 1.5 at 4 months and increasing to a score of
11.2 at 12 months of age. The time points of 4 and 7 months
of age were selected to determine biomarkers indicative of
early events occurring in the development of OA. Changes
that developed in the medial tibial plateau between 4 and 7
months included ﬁbrillation of the superﬁcial zone, and pro-
teoglycan loss in the superﬁcial and middle zones (Fig. 1).
In coronal sections of guinea pig knees, TG2 was de-
tected in the superﬁcial and middle zones of the cartilage
by 4 months of age (Fig. 1). By 7 months of age, TG2
was prominent in both the cartilage, especially superﬁcially
(Fig. 1) and in developing osteophytes (Fig. 2) but less in
hypocellular regions of cartilage. The immunostaining in os-
teophytes mirrored that of the other stereotypic chondrocyte
Fig. 1. TG isoenzymes, TG isopeptide bonds, Factor XIIIA, and MMP-13 in the medial tibial plateau of the Hartley guinea pig knee at 4, 7 and
12 months of age. Coronal guinea pig knee sections were assessed from animals during the course of OA at 4, 7 and 12 months of age.
Histological changes were evaluated by toluidine blue staining (panel A, F, K). Immunohistochemistry was utilized to examine TG2 (panels
B, G, L), FXIIIA (panels C, H, M), TG-catalyzed N-epsilon gamma glutamyl lysine isopeptide bonds (cross-links XL) (panels D, I, N) and
MMP-13 (panels E, J, O), with positive results indicated by brown staining, as described in the Methods. Magniﬁcation bars: Panel
K¼ 500 mm and Panel O¼ 50 mm.
1058 J. L. Huebner et al.: TG2 as osteoarthritis biomarker
Fig. 2. TG isoenzymes and TG isopeptide bonds in osteophytes of the Hartley guinea pig knee OA at 4, 7, and 12 months of age. Coronal
guinea pig knee sections were assessed from animals at 4, 7, and 12 months of age, as in Fig. 1 above, with evaluation by toluidine blue
staining (panels A, F, K) and immunohistochemistry for TG2 (panels B, G, L), FXIIIA (panels C, H, M), TG-catalyzed N-epsilon gamma glu-
tamyl lysine isopeptide bonds (panels D, I, N), and Type X collagen (panels E, J, and O) with positive results indicated by brown staining.
Magniﬁcation bar¼ 100 mm.
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Fig. 3. Correlation of synovial ﬂuid TG2, but not the TG isoenzyme FXIIIA, to total histological score of OA in Hartley guinea pigs. Correlations
of levels of synovial ﬂuid TG2 and FXIIIA by ELISA with histological evidence of chondropathy by grading of articular cartilage structure, in
Hartley guinea pigs 7e18 months of age, as described in the Methods. Panel A: Concentrations of TG2 (in pg/ml) in guinea pig synovial ﬂuid
correlated positively with total histological score from 7 to 18 months of age (r¼ 0.46, P¼ 0.01). Panel B: Concentrations of FXIIIA (in pg/ml) in
the guinea pig synovial ﬂuid did not signiﬁcantly correlate with total histological score from 7 to 18 months of age (r¼ 0.16, P¼ 0.41).
1060 J. L. Huebner et al.: TG2 as osteoarthritis biomarkerhypertrophy markers12, MMP-13 in cartilage (Fig. 1), and
type X collagen in osteophytes (Fig. 2). Developing osteo-
phytes at 7 months also demonstrated robust formation of
TG-catalyzed isopeptide bonds and expression of FXIIIA
(Fig. 2). Synovial TG2 immunostaining was prominent at 7
months and faint but present at 4 and 12 months (not
shown). TG-catalyzed N-epsilon gamma glutamyl lysine
cross-links (isopeptide bonds) and expression of the TG
isoenzyme FXIIIA increased from 4 to 7 months, particularly
in the middle and superﬁcial zones (Fig. 1). Immmunostain-
ing for TG2, FXIIIA, and TG-catalyzed isopeptide bonds
was less intense in established osteophytes at 12 months
of age compared with developing osteophytes at 7 months,
in association with the evolution to osteophyte calciﬁcation
at the joint margins.SYNOVIAL FLUID TG2 IS A BIOMARKER OF OA SEVERITY IN
HARTLEY GUINEA PIG KNEESConcentrations of TG2 protein in Hartley guinea pig knee
synovial ﬂuid, measured between 7 and 18 months of age,
correlated signiﬁcantly with total histological score from 7 to
18 months of age (r¼ 0.47, P¼ 0.014) [Fig. 3(A)]. TG2 con-
centrations also correlated with synovial ﬂuid COMP
(r¼ 0.39, P¼ 0.05). The association of TG2 with histologi-
cal outcome remained signiﬁcant after adjusting for theeffects of age, weight, and COMP. As a comparator for
TG isoenzymes, we assessed synovial ﬂuid levels of
FXIIIA. There was no association of the FXIIIA synovial ﬂuid
levels from 7 to 18 months of age with total histological
score [Fig. 3(B): r¼ 0.16, P¼ 0.41].ARTICULAR CHONDROCYTE TG2 mRNA IS ASSOCIATED WITH
CHONDROCYTE HYPERTROPHY AND COINCIDENT WITH
HISTOLOGICAL OA IN HARTLEY GUINEA PIG KNEESFrom 2 to 18 months of age, the medial cartilage TG2
mRNA expression was signiﬁcantly correlated with the
mean total histological score, as well as with medial com-
partment OA score (r¼ 1.0, P¼ 0.003). In contrast, there
was no signiﬁcant correlation between FXIIIA mRNA ex-
pression and total histological score from 2 to 18 months
of age (r¼ 0.71, P¼ 0.136). Steady-state mRNA levels of
MMP-13, ADAMTS-5, type X:type II collagen ratio in-
creased in the medial compartment of the Hartley guinea
pigs at 12 months of age (Fig. 4). Under these conditions,
steady-state mRNA expression of TG2 in guinea pig carti-
lage was detectable at low levels in the lateral compartment
and increased progressively from 4 to 18 months of age in
the tibial plateau medial compartment (Fig. 4).
Strain 13 guinea pigs have a markedly decreased sus-
ceptibility to spontaneous knee OA in comparison to the
Fig. 4. Changes with increasing age in steady-state MMP-13, ADAMTS-5, type II:type X collagen, and TG2 mRNA levels in Hartley guinea pig
cartilage of the lateral and medial tibial plateau. Cartilage was harvested separately from the medial and lateral tibial plateau of the knee joints
of guinea pigs at each time point and pooled from 6 animals at each time point for RNA isolation and qPCR analysis of expression of mRNAs
in triplicate, as described in the Methods. The student’s t-test determined the signiﬁcance of the alterations between medial and lateral tibial
plateau samples. *P< 0.05.
1061Osteoarthritis and Cartilage Vol. 17, No. 8Hartley strain35. We observed higher levels of TG2 mRNA
in Hartley than Strain 13 guinea pig knees, and particularly
so in the medial compartment (P¼ 0.0017) (Fig. 5). Though
levels of ADAMTS-5 mRNA were also elevated in the me-
dial compartment at 12 months of age, this expression pat-
tern was not speciﬁc to the Hartley strain guinea pigs
[Fig. 5(D)]. In contrast, at 2 months of age, prior to evidence
of histological OA, compared to the Strain 13 guinea pig,
the type X:type II collagen mRNA ratio was signiﬁcantly
greater in the Hartley guinea pigs in both the medial and lat-
eral compartments (P< 0.0001) [Fig. 5(C)]. In addition,
mRNA levels of MMP-13 and the type X:type II collagen
mRNA ratio were signiﬁcantly higher in the medial tibial pla-
teau of the Hartley compared to the Strain 13 guinea pigs at
12 months of age [Fig. 5(B, C), P< 0.0001].Discussion
Hartley guinea pig spontaneous knee OA, like human
OA, is mediated by multiple factors, including obesity, al-
tered biomechanicals, aging, and chondrocyte nitric oxide
generation and mitochondrial dysfunction32e39. Articular
cartilages in OA in both species express MMPs-1,3,13and aggrecanases34,40, and biomarkers reﬂective of OA se-
verity (e.g., keratan sulfate (KS)35, cartilage oligomeric ma-
trix protein (COMP)36, and markers of type II collagen
degradation and synthesis38). Several biomarkers evalu-
ated in guinea pig synovial ﬂuid correlate with severity of
joint disease, whereas serum markers todate have not re-
ﬂected localized disease38. Here, guinea pig OA cartilage
and synovial ﬂuid were a platform for examining TG2 as
a biomarker during disease evolution.
Both TG2 synovial ﬂuid protein and knee cartilage mRNA
levels correlated with histological OA grade in Hartley
guinea pig knees. These ﬁndings are in line with the re-
ported direct role of TG2 in promoting cartilage destruction
in OA29, putatively by promoting altered chondrocyte differ-
entiation12,13 and by modifying extracellular matrix14,22. Sy-
novitis may also contribute to synovial ﬂuid TG2 levels and
contribute to the synovial ﬂuid TG2 pool in a disease sever-
ity-speciﬁc manner.
TG2 is the major catalytically active TG in the extracel-
lular matrix in human OA cartilage10, but both TG2 and
FXIIIA undergo physiologic up-regulation in growth plate
hypertrophic chondrocytes and pathologic up-regulation
in OA cartilage9,15,16. Here, cartilage and synovial ﬂuid
FXIIIA mRNA did not correlate with OA severity. Possibly
Fig. 5. Comparison of TG2, type X collagen, and MMP-13, and ADAMTS-5 mRNA expression in Hartley and Strain 13 guinea pig medial tibial
plateau OA cartilages, reveal higher levels of all but ADAMTS-5 in Hartley. RNA was isolated from cartilage harvested separately from the
medial and lateral tibial plateaus pooled from Hartley and Strain 13 guinea pigs at 2 (n¼ 3 each) and 12 months of age (n¼ 8 each), and
qPCR was performed in triplicate as described above for TG2, MMP-13, types X vs type II collagen, and ADAMTS-5. For TG2: 12 months
medial tibial plateau S13 vs Hartley P¼ 0.0017; 12 months lateral tibial plateau S13 vs Hartley P¼ 0.0026. For MMP-13, 12 months medial
plateau S13 vs Hartley P< 0.0001, 2 months lateral plateau S13 vs Hartley P¼ 0.0019. For collagen type X/II ratio; 2 months medial plateau
S13 vs Hartley P< 0.0001; 2 months lateral plateau S13 vs Hartley P< 0.0001; 12 months medial plateau S13 vs Hartley P< 0.0001; 12
months lateral plateau S13 vs Hartley P< 0.0001; ADAMTS-5 12 months medial plateau S13 vs Hartley P¼ 0.0684; 12 months lateral plateau
S13 vs Hartley P¼ 0.3675.
1062 J. L. Huebner et al.: TG2 as osteoarthritis biomarkercontributing to these ﬁndings, TG2 and FXIIIA have distinct
substrate motifs41, and susceptibility to and molecular
mechanisms of proteolysis14,42. There is likely different
stability of TG-catalyzed isopeptide bonds in OA tissue
than of the parent proteins producing these cross-links14
(and possibly of TG isoenzyme mRNA levels). Increased
TG-catalyzed isopeptide bonds in articular cartilage in
early evolution of OA also may reﬂect release of constitu-
tively expressed TG2 and FXIIIA, whose activation from la-
tency is promoted by extracellular exposure to increased
free calcium14. The relatively late increases in TG2
mRNA expression in chondrocytes, in the setting of both
ongoing cartilage repair and decreased cellularity, are con-
sistent with accelerated chondrocyte maturation to hyper-
trophy, validated by type X collagen expression, now
well described as contributing to advancing OA18,43.
Hartley and Strain 13 guinea pigs similarly demonstrated
increased ADAMTS-5 mRNA44 expression at 12 months of
age, but Strain 13 guinea pig knee cartilage showed lower
expression of genes associated with the hypertrophic carti-
lage phenotype, even at 2 months of age, consistent with
less severe OA in this model. One speculates thatpredisposition of Hartley guinea pig chondrocytes to hyper-
trophic differentiation could promote increased susceptibility
to OA relative to Strain 13.
Limitations of this study included uncertainty as to relative
contributions of synovium, inﬁltrating leukocytes, and carti-
lage to synovial ﬂuid TG2. In view of limiting amounts of tis-
sue, we studied few time points, and could thereby have
missed initial up-regulation of TG2, FXIIIA, and type X col-
lagen mRNA. Kamekura et al. have shown that increased
type X collagen expression develops prior to OA progres-
sion in response to surgically-induced mouse knee joint in-
stability18. Here, Type X collagen expression was detected
within articular cartilages of Hartley guinea pigs by 4 months
of age, possibly indicative of early OA or reﬂective of basal
expression of type X collagen, which is a normal ﬁnding in
mouse articular cartilage45.
We conclude that TG2 expressed by chondrocytes in situ
and released into the synovial ﬂuid, is a biomarker of OA se-
verity. TG2 mRNA expression in this model system also co-
incides with manifestations of the articular chondrocyte
hypertrophic differentiation response associated with type
X collagen and MMP-13 expression. Because TG2 drives
1063Osteoarthritis and Cartilage Vol. 17, No. 8both hypertrophy of cultured chondrocytes12 and progres-
sion of articular cartilage destruction in mouse knee OA21,
TG2 appears to be a prime example of a direct modulator
of chondrocyte differentiation that affects the phenotype of
tissue repair in OA.Conﬂict of interest
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